MARKET

PIRS

PIRS

Pieris Pharmaceu
NASDAQ
0.7500
-0.0700
-8.54%
After Hours: 0.7499 -0.0001 -0.01% 18:14 05/26 EDT
OPEN
0.8200
PREV CLOSE
0.8200
HIGH
0.8880
LOW
0.7500
VOLUME
758.20K
TURNOVER
0
52 WEEK HIGH
2.115
52 WEEK LOW
0.7181
MARKET CAP
61.51M
P/E (TTM)
-1.3487
1D
5D
1M
3M
1Y
5Y
Pieris Pharmaceu: General statement of acquisition of beneficial ownership
Press release · 05/22 21:13
Pieris Pharmaceu: Initial statement of beneficial ownership of securities
Press release · 05/22 21:13
Pieris Pharmaceuticals Announces Presentation Of Encouraging Preclinical Data For PRS-400 At ATS 2023 International Conference
Benzinga · 05/22 12:10
BRIEF-Pieris Pharmaceuticals Inc Received Notice Of Delisting From Nasdaq
Reuters · 05/19 20:22
Pieris Pharmaceu: Current report
Press release · 05/19 16:07
Pieris Pharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent Application 17/499,640 Titled "Lipocalin Muteins With Binding Affinity For Lag-3 (For The Treatment Of Human Diseases Such As Cancer, And Infectious And Autoimmune Diseases)"
Benzinga · 05/17 18:14
Pieris Pharmaceuticals: Expanding Elarekibep (AZD1402) Trial Finally Has Active And Completed Sites
Seeking Alpha · 05/17 04:55
Pieris Pharmaceuticals: Q1 Earnings Insights
Benzinga · 05/10 14:15
More
About PIRS
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline includes an inhaled IL-4Ra antagonist Anticalin protein to treat asthma, an immuno-oncology (IO), bispecific targeting HER2 and 4-1BB, and an IO bispecific targeting PD-L1 and 4-1BB. Its lead respiratory Anticalin based drug candidate, elarekibep, antagonizes IL-4Ra, thereby inhibiting IL-4 and IL-13, two cytokines, which are small proteins mediating signaling between cells within the human body, known to be key mediators in the inflammatory cascade that drive the pathogenesis of asthma and other inflammatory diseases. Its IO portfolio also includes additional drug candidates beyond PRS-344/S095012 that are multi-specific Anticalin-based fusion proteins designed to engage immunomodulatory targets, comprising a variety of multifunctional biotherapeutics.

Webull offers kinds of Pieris Pharmaceuticals Inc stock information, including NASDAQ:PIRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PIRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PIRS stock methods without spending real money on the virtual paper trading platform.